-- 
Vertex Shares Fall on Little-Changed Incivek Sales

-- B y   A n n a   E d n e y
-- 
2011-10-17T13:42:05Z

-- http://www.bloomberg.com/news/2011-10-17/vertex-shares-fall-on-little-changed-incivek-sales.html
Vertex Pharmaceuticals Inc. (VRTX) , seller
of the hepatitis C drug Incivek, fell 3 percent after sales of
the medicine were little changed.  Vertex, based in Cambridge,  Massachusetts , dropped to
$41.98 at 9:39 a.m. New York time. IMS Health Inc., a
prescription-data company, said sales of Incivek in the first
week of October were “relatively flat over September,”  Jason
Kantor , an analyst at  RBC Capital Markets  wrote in a note.  To contact the reporter on this story:
Anna Edney in Washington at 
 aedney@bloomberg.net   To contact the editor responsible for this story:
Bruce Rule at 
 brule1@bloomberg.net  